Tetra Biopharma

Tetra Bio-Pharma (TBP.T) has announced the start of the REBORN1© clinical trial, designed to evaluate the effect of QIXLEEF™, the Company’s inhaled proprietary drug formulation. During this study, QIXLEEF™…
Tetra Bio-Pharma (TBP.T), a leader in cannabinoid-derived drug discovery and development, has announced that is has signed a Definitive Agreement with DanCann Pharma for the exclusive distribution of Reduvo™…
Tetra Bio-Pharma (TBP.T), a leader in cannabinoid-derived drug discovery and development, announced today that it has been granted a Health Canada Drug Establishment License (DEL) to distribute REDUVO soft…
Tetra Bio-Pharma (TBP.T) has shipped Qixleef, its investigational new drug, to the United States for initiation of the REBORN1 study. The REBORN1 study will investigate cannabis as an alternative…
It’s time for your Tuesday cannabis rundown. First up: The Green Organic Dutchman Holdings (TGOD.T) signed a letter of intent with the Societe quebecoise du cannabis (SQDC) before its…
Tetra Biopharma (TBP.V) has been busy conducting clinical development programs of two potential products, the first being Quixleef and the second Plenitude. Both involve dealing with uncontrolled pain in…